PTHS (Pelthos Therapeutics) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 08, 2026)


PTHS Pelthos Therapeutics Inc PTHS
8 GF Score
Price $25.85
! 4 Warning Signs
View Full Analysis

What is Pelthos Therapeutics 5-Year Yield-on-Cost %?

Pelthos Therapeutics PTHS +5.09% 8 5-Year Yield-on-Cost % is 0.00 as of Jul. 08, 2026. GuruFocus rates PTHS with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 153 Biotechnology companies, Pelthos Therapeutics ranks worse than 653594.12% on this metric.

Pelthos Therapeutics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Pelthos Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



PTHS's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.64
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Pelthos Therapeutics  (AMEX:PTHS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Pelthos Therapeutics 5-Year Yield-on-Cost % Related Terms


PTHS vs CGTX, BDTX, CBUS: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Pelthos Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pelthos Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pelthos Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Pelthos Therapeutics's 5-Year Yield-on-Cost % falls into.


PTHS
8GF Score
Pelthos Therapeutics Inc PTHS
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pelthos Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Pelthos Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Pelthos Therapeutics (PTHS) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 08, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pelthos Therapeutics and its competitors. According to the industry distribution chart, Pelthos Therapeutics ranks #999999 out of 153 companies in the Biotechnology industry.
Is Pelthos Therapeutics' 5-Year Yield-on-Cost % too high?
Pelthos Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Pelthos Therapeutics ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pelthos Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' 5-Year Yield-on-Cost % compare to CGTX and BDTX?
According to the Biotechnology industry distribution chart, Pelthos Therapeutics ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Pelthos Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.64, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pelthos Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pelthos Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Pelthos Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pelthos Therapeutics Business Description

Address 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score

Get the complete analysis for PTHS

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.85
Price